Search Results
Diese Website durchsuchen
548 Ergebnisse gefunden mit einer leeren Suche
- Eli Lilly partners with METiS TechBio in AI-driven lipid nanoparticle collaboration worth up to $1.1 billion in milestones
Eli Lilly and METiS TechBio have entered an AI-enabled lipid nanoparticle discovery collaboration carrying up to approximately $1.1 billion in potential milestone payments. The partnership will use METiS TechBio's AiLNP platform to discover and optimise ionizable lipids for tissue-specific lipid nanoparticle delivery, with the aim of improving the targeting and biodistribution of therapeutic modalities. METiS is eligible for an upfront payment in the low double-digit millions of US dollars and approximately $1.1 billion in contingent development, regulatory and commercial milestones, while the technology remains at the research stage. Field Content Article Type Deals Companies Eli Lilly; METiS TechBio Deal Type Strategic research collaboration Announcement Date 19 October 2026 Technology Focus AI-driven lipid nanoparticle discovery and optimisation Technology Platform METiS AiLNP platform Research Focus Tissue-specific lipid nanoparticle delivery technologies Key Technology Component Ionizable lipid discovery and optimisation Therapeutic Application Delivery and biodistribution of therapeutic modalities Upfront Payment Low double-digit millions of US dollars; exact amount not disclosed in supplied summary Potential Milestone Payments Up to approximately $1.1 billion Milestone Categories Development; regulatory; commercial Total Potential Deal Value Upfront payment plus up to approximately $1.1 billion in contingent milestones Royalties Not confirmed in supplied summary Geography United States; Hong Kong Development Stage Research and discovery Clinical Status No clinical efficacy established by this collaboration announcement What Happened Eli Lilly entered a strategic research collaboration with METiS TechBio to develop tissue-specific lipid nanoparticle delivery technologies using AI. Why It Matters More precise delivery technologies could help address limitations in how therapeutic molecules reach intended tissues. Strategic Rationale Lilly gains access to METiS's AI-enabled nanoparticle discovery capabilities while METiS receives upfront funding and potential milestone opportunities. Potential Impact The collaboration could support future development of targeted delivery technologies if research objectives are achieved. Key Takeaway The agreement includes an upfront payment in the low double-digit millions and up to approximately $1.1 billion in contingent milestones, not guaranteed transaction proceeds. What to Watch Research milestones, delivery platform validation, programme selection, preclinical results and potential clinical development. Primary Source METiS TechBio Primary Source URL https://metistechbio.com/en/qyxw/253.html Relevant Date 19 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- South Korea approves Jascayd nerandomilast for idiopathic pulmonary fibrosis
South Korea has authorised Jascayd (nerandomilast) for idiopathic pulmonary fibrosis, providing a new national treatment option for patients with progressive lung scarring. The Ministry of Food and Drug Safety granted marketing approval for the phosphodiesterase-4 inhibitor following an expedited review under its Global Innovative Products on Fast Track programme. The decision represents a separate South Korean authorisation from Jascayd's earlier Saudi approval and expands the drug's regulatory footprint in a disease with substantial unmet treatment needs. Field Content Article Type Approvals Drug Name Jascayd Generic Name Nerandomilast Regulatory Authority South Korea Ministry of Food and Drug Safety Regulatory Decision National marketing authorisation Indication Idiopathic pulmonary fibrosis Therapeutic Area Respiratory medicine; fibrotic lung disease Therapeutic Modality Small-molecule phosphodiesterase-4 inhibitor Mechanism of Action Phosphodiesterase-4 inhibition Regulatory Pathway Global Innovative Products on Fast Track programme Approval Date 15 October 2026 Geography South Korea Company Not confirmed in the supplied summary Patient Population Patients with idiopathic pulmonary fibrosis; specific label restrictions not confirmed in supplied summary Clinical Evidence Specific study results not provided in supplied summary What Happened South Korea's Ministry of Food and Drug Safety approved Jascayd nerandomilast for idiopathic pulmonary fibrosis. Why It Matters The authorisation introduces another treatment option for a progressive fibrotic lung disease and broadens the availability of a therapy with a different mechanism from established antifibrotics. Regulatory Context The decision followed expedited review and is distinct from the Saudi SFDA approval previously covered by NEON. Key Takeaway Jascayd has received a new national marketing authorisation in South Korea for idiopathic pulmonary fibrosis. What to Watch Commercial launch timing, reimbursement decisions, prescribing information, clinical adoption and additional territorial approvals. Primary Source Seoul Economic Daily Relevant Date 15 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Mankind Pharma agrees €48 million acquisition of 70% stake in Armed Cell Therapeutics to enter CAR-T oncology
Mankind Pharma has agreed to acquire a 70% stake in Belgium's Armed Cell Therapeutics for €48 million, marking its entry into next-generation CAR-T oncology therapies. The transaction, conducted through Mankind Pharma's Netherlands subsidiary, will provide a majority interest in Armed Cell Therapeutics and its investigational cell therapy programmes for cancers including non-Hodgkin lymphoma and small-cell lung cancer. The investment expands Mankind's strategic focus into advanced oncology treatments and provides exposure to emerging CAR-T approaches, including research into generating CAR-T cells directly within the body. Field Content Article Type Deals Companies Mankind Pharma; Armed Cell Therapeutics Deal Type Majority stake acquisition agreement Acquirer Mankind Pharma through its Netherlands subsidiary Target Armed Cell Therapeutics Target Country Belgium Equity Stake 70% Transaction Consideration €48 million Transaction Status Definitive acquisition agreement announced Therapeutic Modality Chimeric antigen receptor T-cell therapies Therapeutic Areas Oncology; non-Hodgkin lymphoma; small-cell lung cancer Technology Focus Next-generation CAR-T therapies including investigational in vivo CAR-T approaches Development Stage Investigational programmes Geography India; Netherlands; Belgium What Happened Mankind Pharma agreed to acquire a 70% stake in Armed Cell Therapeutics for €48 million. Why It Matters The transaction marks Mankind Pharma's strategic entry into advanced cell therapies and adds investigational oncology assets to its development interests. Strategic Rationale Mankind seeks to diversify into next-generation cancer treatments through a controlling investment in a specialised European biotechnology company. Potential Impact The acquisition could support development of CAR-T approaches for haematological and solid-tumour indications if investigational programmes advance successfully. Key Takeaway Mankind Pharma has agreed to invest €48 million for a majority stake in Armed Cell Therapeutics to establish a position in CAR-T oncology. What to Watch Transaction completion, pipeline disclosures, preclinical and clinical milestones, and progress in in vivo CAR-T development. Primary Source Mankind Pharma Relevant Date 15 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- AstraZeneca signs $1.5 billion AI drug discovery collaboration with insitro for cardiometabolic diseases
AstraZeneca and insitro have entered a $1.5 billion AI-enabled drug discovery collaboration targeting difficult-to-treat cardiometabolic diseases. The agreement will use insitro's Virtual Human AI platform to identify therapeutic targets and develop candidates for metabolic dysfunction-associated steatohepatitis and cardiomyopathies, with AstraZeneca securing exclusive worldwide rights to selected programmes. insitro will receive $40 million upfront and may earn approximately $1.46 billion in development and commercial milestones plus potential single-digit royalties, with most of the headline deal value contingent on future progress. Field Content Article Type Deals Companies AstraZeneca; insitro Deal Type Strategic research collaboration and licensing agreement Potential Deal Value Approximately $1.5 billion excluding royalties Upfront Payment $40 million Potential Milestone Payments Approximately $1.46 billion in development and commercial milestones Royalties Potential single-digit royalties Technology insitro Virtual Human AI platform Therapeutic Areas Cardiometabolic diseases; metabolic dysfunction-associated steatohepatitis; cardiomyopathies Research Focus AI-enabled therapeutic target identification and drug candidate development Licensing Rights Exclusive worldwide rights to selected programmes for AstraZeneca Development Stage Research and discovery Geography Worldwide What Happened AstraZeneca entered a strategic collaboration and licensing agreement with insitro to discover and develop treatments for difficult-to-treat cardiometabolic diseases. Why It Matters The partnership combines AI-driven human disease modelling with pharmaceutical development capabilities to investigate therapeutic targets in areas of substantial unmet medical need. Strategic Rationale AstraZeneca gains access to insitro's AI platform and selected programmes while insitro receives upfront funding and contingent development and commercial opportunities. Key Takeaway The agreement offers approximately $1.5 billion in potential consideration but only $40 million is identified as an upfront payment. What to Watch Target identification, programme selection, preclinical candidate development, milestone achievements and clinical development plans. Primary Source AstraZeneca Relevant Date 15 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA clears Stryker Sonopet 3 ultrasonic surgical tissue removal platform
The FDA has cleared Stryker's Sonopet 3 ultrasonic surgical platform, introducing enhanced bone and soft-tissue removal capabilities for surgical procedures. The Sonopet 3 system incorporates updated ultrasonic tissue removal technology with enhanced power, precision and surgeon-controlled features, including RISE workflow integration and Pulse Control. Initial clinical use is expected in October 2026, with broader commercial availability planned later in the autumn, following the FDA's 510(k) clearance. Field Content Article Type Approvals Device Name Sonopet 3 Company Stryker Regulatory Authority U.S. Food and Drug Administration Regulatory Decision 510(k) clearance Device Type Ultrasonic surgical tissue removal system Clinical Application Ultrasonic bone and soft-tissue removal during surgery Technology Ultrasonic surgical tissue removal Key Features Enhanced power and precision; surgeon-controlled functionality; RISE workflow integration; Pulse Control Workflow Feature RISE workflow integration Control Feature Pulse Control Therapeutic Area Surgical technology; medical devices Geography United States Initial Clinical Use Expected October 2026 Broader Commercial Availability Planned for later autumn 2026 What Happened The FDA granted 510(k) clearance for Stryker's Sonopet 3 ultrasonic surgical platform. Why It Matters The clearance enables introduction of an updated surgical platform designed to support controlled removal of bone and soft tissue. Potential Impact Enhanced surgical control and workflow features may support adoption in procedures requiring precise ultrasonic tissue removal. Regulatory Context Medical device clearance rather than pharmaceutical marketing authorisation Key Takeaway Stryker's Sonopet 3 has secured FDA 510(k) clearance ahead of planned US clinical use and commercial rollout. What to Watch Initial clinical deployment, commercial availability, surgeon feedback, adoption rates and future procedural performance evidence. Primary Source Stryker Relevant Date 14 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- UK MHRA launches 2030 strategy to modernise AI, medical device and personalised medicine regulation
The UK's Medicines and Healthcare products Regulatory Agency has launched its 2030 strategy to modernise regulation of AI-enabled healthcare, medical devices and personalised medicines. The five-year strategy outlines plans to update regulatory oversight, improve efficiency, strengthen patient participation and support access to innovative medicines and medical technologies. The announcement establishes the MHRA's regulatory priorities through 2030 rather than immediately imposing new binding requirements, making future implementation measures important for pharmaceutical and medtech companies. Field Content Article Type Industry Updates Regulatory Authority Medicines and Healthcare products Regulatory Agency Jurisdiction United Kingdom Policy Initiative MHRA 2030 Strategy Policy Type Five-year regulatory strategy Strategy Horizon Through 2030 Key Focus Areas Artificial intelligence in healthcare; medical devices; personalised medicines; regulatory efficiency; patient participation Affected Sectors Pharmaceuticals; biotechnology; medical technology; digital health Regulatory Status Strategic policy direction; not an immediate set of new binding requirements AI Regulation Modernisation of regulatory oversight for AI-enabled healthcare technologies Medical Device Regulation Planned improvements to oversight and regulatory processes for medical technologies Personalised Medicines Support for regulatory approaches suited to innovative and personalised treatments Patient Participation Greater emphasis on patient involvement in regulatory decision-making What Happened The MHRA published its strategy setting out regulatory modernisation priorities through 2030. Why It Matters The strategy signals how the UK regulator intends to adapt oversight to rapidly evolving healthcare technologies while improving regulatory efficiency and patient access. Industry Implications Developers of medicines, AI-enabled technologies and medical devices may need to adapt to future guidance and regulatory reforms arising from the strategy. Relationship to Earlier Policy Distinct from the UK government's acceptance of healthcare AI commission recommendations announced on 7 October 2026 Key Takeaway The MHRA has outlined a long-term regulatory modernisation agenda rather than announcing immediately effective new legal requirements. What to Watch Implementation plans, consultation documents, AI-specific guidance, medical device reforms and measurable regulatory performance changes. Primary Source UK Government and MHRA Relevant Date 14 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Genentech Enspryng as first at-home subcutaneous treatment for thyroid eye disease
The FDA has approved Genentech's Enspryng as the first at-home subcutaneous treatment option for adults with thyroid eye disease. Enspryng (satralizumab-mwge), an interleukin-6 receptor inhibitor, can be administered subcutaneously with maintenance dosing every four weeks, expanding its use beyond its previously authorised indication. The approval was supported by Phase III SatraGO-1 and SatraGO-2 studies, which provided evidence of improvements in eye bulging and double vision among patients with thyroid eye disease. Field Content Article Type Approvals Drug Name Enspryng Generic Name Satralizumab-mwge Company Genentech Parent Company Roche Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Expanded indication approval Approval Date 15 October 2026 New Indication Thyroid eye disease in adults Patient Population Adults with thyroid eye disease Therapeutic Area Ophthalmology; autoimmune inflammatory disease Drug Class Interleukin-6 receptor inhibitor Mechanism of Action IL-6 receptor inhibition Administration Route Subcutaneous injection Administration Setting At-home administration Maintenance Dosing Every four weeks Supporting Clinical Studies Phase III SatraGO-1 and SatraGO-2 Reported Clinical Outcomes Improvements in eye bulging and double vision Approval Significance First FDA-approved at-home subcutaneous treatment option for thyroid eye disease Previous Indication Previously approved for another indication; details not specified in supplied summary Geography United States What Happened The FDA expanded Enspryng's approval to include adults with thyroid eye disease. Why It Matters The approval introduces an at-home injectable treatment option for a condition that can cause substantial visual and functional impairment. Clinical Evidence Phase III SatraGO-1 and SatraGO-2 studies supported the decision; specific efficacy percentages were not provided in the supplied summary. Potential Impact At-home administration and four-week maintenance dosing may offer greater treatment flexibility for eligible patients. Key Takeaway Enspryng is now FDA-approved for adult thyroid eye disease as an at-home subcutaneous treatment. What to Watch US commercial availability, reimbursement, physician adoption, patient experience and longer-term treatment outcomes. Primary Source Genentech Primary Source URL https://www.gene.com/media/news-features/fda-approves-first-in-class-il-6r-inhibitor-as-the-first-and-only-at-home-subcutaneous-treatment-option-for-thyroid-eye-disease-ted Relevant Date 15 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Biodesix partners with Vanderbilt to develop AI-enabled lung nodule diagnostics combining imaging and blood biomarkers
Biodesix is collaborating with Vanderbilt University and Vanderbilt Health to develop an AI-enabled lung nodule risk assessment test combining imaging and blood-based biomarkers. The programme will use radiomics-based imaging analysis alongside Biodesix's existing Nodify Lung blood diagnostics portfolio to investigate a multimodal approach to evaluating lung nodules. Initial research data are scheduled for presentation in December 2026, with potential commercial availability anticipated in 2028, although the new diagnostic test remains under development and has not received regulatory clearance. Field Content Article Type Deals Companies Biodesix; Vanderbilt University; Vanderbilt Health Deal Type Diagnostics research and development collaboration Therapeutic Area Pulmonology; lung cancer diagnostics Development Focus AI-enabled lung nodule risk assessment Technology Radiomics-based imaging analysis combined with blood biomarkers Diagnostic Modality Multimodal diagnostic testing Existing Product Portfolio Biodesix Nodify Lung blood-based diagnostics Research Objective Develop a lung nodule risk assessment test integrating imaging and blood-based biomarkers AI Application Analysis of imaging-derived biomarkers to support risk assessment Development Stage Research and development Regulatory Status Investigational diagnostic; no new regulatory clearance reported Initial Data Presentation Scheduled for 3 December 2026 Anticipated Commercial Availability 2028; subject to development progress Financial Terms Not disclosed in supplied summary Geography United States What Happened Biodesix announced a development collaboration with Vanderbilt University and Vanderbilt Health for an AI-enabled lung nodule diagnostic test. Why It Matters Combining imaging and blood-based biomarkers could support more comprehensive assessment of lung nodules and help inform clinical decision-making if validated. Strategic Rationale Biodesix aims to expand its diagnostics pipeline beyond blood-based tests by integrating radiomics and AI capabilities. Potential Impact The programme could create a new multimodal diagnostic option for lung nodule evaluation following successful validation and any required regulatory processes. Key Takeaway Biodesix is developing an AI-enabled lung nodule test with Vanderbilt; the product remains investigational and is not yet commercially available. What to Watch Initial data presentation on 3 December 2026, validation results, regulatory plans and progress toward the anticipated 2028 commercial timeline. Primary Source Biodesix Primary Source URL https://biodesix.gcs-web.com/news-releases/news-release-details/biodesix-adds-digital-diagnostics-lung-pipeline-creating-new Relevant Date 19 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Merck KGaA agrees $1.3 billion acquisition of Silence Therapeutics to expand rare disease siRNA pipeline
Merck KGaA has agreed to acquire Silence Therapeutics in an all-cash transaction valued at approximately $1.3 billion in equity, expanding its RNA interference pipeline. The acquisition will add Silence Therapeutics' siRNA development platform and divesiran, an investigational Phase III-ready treatment candidate for polycythemia vera, to Merck's pharmaceutical research portfolio. Merck will pay $20 per American depositary share, representing approximately $1.3 billion in equity value and $1.1 billion in enterprise value, with completion subject to customary closing conditions. Field Content Article Type Deals Companies Merck KGaA; Silence Therapeutics Deal Type Definitive all-cash acquisition agreement Acquirer Merck KGaA Target Silence Therapeutics Target Country United Kingdom Offer Price $20 per American depositary share Equity Value Approximately $1.3 billion Enterprise Value Approximately $1.1 billion Transaction Structure All-cash acquisition Transaction Status Definitive agreement signed; completion pending Agreement Execution Date 18 October 2026 Announcement Date 19 October 2026 Key Pipeline Asset Divesiran Key Asset Development Stage Phase III-ready Key Asset Indication Polycythemia vera Therapeutic Modality Small interfering RNA (siRNA) Technology Platform RNA interference drug development Therapeutic Areas Rare diseases; haematology Closing Conditions Customary transaction closing conditions What Happened Merck KGaA agreed to acquire Silence Therapeutics for approximately $1.3 billion in equity value. Why It Matters The acquisition expands Merck's capabilities in RNA interference therapeutics and adds a late-stage investigational candidate for a rare blood cancer. Strategic Rationale Merck gains access to Silence's siRNA technology platform and divesiran development programme. Key Takeaway The transaction has an approximately $1.3 billion equity value and $1.1 billion enterprise value; these are distinct valuation measures. What to Watch Transaction completion, divesiran Phase III development plans, regulatory milestones and integration of Silence's RNAi platform. Primary Source Merck KGaA Primary Source URL https://www.emdgroup.com/en/news/silence-therapeutics-19-10-2026.html Relevant Date 19 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA grants accelerated approval to GSK Jemperli for MSI-H or dMMR locally advanced rectal cancer
The FDA has granted accelerated approval to GSK's Jemperli for previously untreated MSI-H or dMMR locally advanced rectal cancer, introducing a potentially organ-preserving immunotherapy approach. Jemperli (dostarlimab-gxly), a PD-1 inhibitor, is now authorised for adults with Stage II or III locally advanced rectal cancer characterised by microsatellite instability-high or mismatch repair-deficient disease, as identified by an FDA-authorised test. The decision was supported by the single-arm Phase II AZUR-1 study involving 154 patients and may enable some eligible individuals to avoid conventional chemotherapy, radiation or surgery, subject to clinical assessment and follow-up. Field Content Article Type Approvals Drug Name Jemperli Generic Name Dostarlimab-gxly Company GSK Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Accelerated approval Approval Date 19 October 2026 New Indication Previously untreated locally advanced rectal cancer with MSI-H or dMMR status Patient Population Adults with Stage II or III locally advanced MSI-H or dMMR rectal cancer Biomarker Requirement Microsatellite instability-high or mismatch repair-deficient status determined by an FDA-authorised test Therapeutic Area Oncology; colorectal cancer Drug Class PD-1 immune checkpoint inhibitor Mechanism of Action PD-1 inhibition Supporting Clinical Study Phase II AZUR-1 Clinical Trial Design Single-arm Phase II study Study Population 154 patients Potential Clinical Benefit May allow selected patients to avoid chemotherapy, radiation or surgery depending on response and clinical assessment Geography United States What Happened The FDA granted accelerated approval to Jemperli for previously untreated Stage II or III MSI-H or dMMR locally advanced rectal cancer. Why It Matters The approval introduces an immunotherapy approach that may reduce the need for conventional multimodal treatment in a biomarker-defined patient population. Clinical Evidence The decision was supported by the Phase II AZUR-1 study involving 154 patients; specific response statistics were not provided in the supplied summary. Regulatory Context Accelerated approval; any confirmatory requirements were not specified in the supplied summary Key Takeaway Jemperli is now authorised for eligible adults with previously untreated MSI-H or dMMR locally advanced rectal cancer under the FDA's accelerated approval pathway. What to Watch Confirmatory evidence requirements, longer-term outcomes, organ preservation, clinical guideline updates and real-world adoption. Primary Source U.S. Food and Drug Administration Primary Source URL https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-dostarlimab-locally-advanced-rectal-cancer Relevant Date 19 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- Roche signs Hansoh Pharma oncology ADC collaboration with more than $15 billion in potential milestones
Roche and Hansoh Pharma have signed a major oncology licensing agreement involving antibody-drug conjugates, with more than $15 billion in potential milestone payments. The collaboration covers a portfolio of ADC programmes targeting multiple cancers, including two existing programmes and potential additional projects, with Roche responsible for later-stage development and commercialisation outside Greater China. Hansoh is eligible for $400 million upfront, $110 million on the first anniversary, more than $15 billion in contingent milestones and royalties, making the agreement one of the largest potential oncology licensing arrangements announced in 2026. Field Content Article Type Deals Companies Roche; Hansoh Pharma Deal Type Strategic collaboration and licensing agreement Therapeutic Area Oncology Therapeutic Modality Antibody-drug conjugates (ADCs) Portfolio Scope Two existing ADC programmes and potential additional projects Upfront Payment $400 million First Anniversary Payment $110 million Potential Milestones More than $15 billion in contingent milestone payments Royalties Additional royalties; rates not disclosed in supplied summary Total Potential Consideration More than $15.51 billion including upfront and first-anniversary payments; contingent milestones are not guaranteed Licensed Territory Outside mainland China, Hong Kong, Macau and Taiwan Roche Responsibilities Later-stage development and commercialisation in licensed territories Hansoh Responsibilities Collaboration on ADC programmes; detailed development responsibilities not confirmed in supplied summary Development Stage Individual programme stages not specified in supplied summary What Happened Roche and Hansoh Pharma entered a new oncology collaboration and licensing agreement covering a portfolio of antibody-drug conjugates. Why It Matters The partnership substantially expands Roche's access to investigational ADC programmes and strengthens its oncology development pipeline. Strategic Rationale Roche gains rights to multiple oncology assets while Hansoh receives substantial upfront funding and opportunities for future milestones and royalties. Previous Collaboration This agreement is distinct from the companies' earlier ADC collaboration. Key Takeaway The agreement provides Hansoh with $400 million upfront and potentially more than $15 billion in milestones; most of the headline value is contingent. What to Watch Programme disclosures, clinical development progress, milestone achievements and regulatory submissions. Primary Source Hansoh Pharma Primary Source URL https://www.hspharm.com/news/news-detail-513518.htm Relevant Date 19 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com
- FDA approves Viatris Ryzumvi eye drops for age-related presbyopia in adults
The FDA has approved Viatris' Ryzumvi eye drops for presbyopia in adults, expanding the product's use beyond reversal of pharmacologically induced pupil dilation. Ryzumvi (phentolamine ophthalmic solution 0.75%) provides a prescription eye-drop treatment option for age-related loss of near focusing ability, offering a non-invasive alternative for eligible adults. Viatris holds exclusive US commercialisation rights through its agreement with Opus Genetics and is evaluating a potential commercial partner for the newly approved presbyopia indication. Field Content Article Type Approvals Drug Name Ryzumvi Generic Name Phentolamine ophthalmic solution Strength 0.75% Company Viatris Development and Licensing Partner Opus Genetics Regulatory Authority U.S. Food and Drug Administration Regulatory Decision Approval of an expanded indication New Indication Treatment of presbyopia in adults Previously Approved Use Reversal of pharmacologically induced pupil dilation Patient Population Adults with presbyopia Therapeutic Area Ophthalmology; vision correction Drug Formulation Prescription ophthalmic solution Treatment Approach Non-invasive pharmacological treatment using eye drops Approval Announcement Date 16 October 2026 Geography United States Commercial Rights Viatris holds exclusive US commercialisation rights through its agreement with Opus Genetics Commercialisation Plans Viatris is evaluating a potential US commercial partner for the presbyopia indication Clinical Evidence Specific pivotal trial results were not provided in the supplied summary What Happened The FDA approved Ryzumvi phentolamine ophthalmic solution 0.75% for the treatment of presbyopia in adults. Why It Matters The approval expands the range of prescription eye-drop treatments available for adults experiencing age-related difficulty focusing on nearby objects. Supporting Context Ryzumvi was previously authorised for reversal of pharmacologically induced pupil dilation; the presbyopia indication represents a separate approved use. Potential Impact The expanded indication may create additional treatment and commercial opportunities in the US presbyopia market. Key Takeaway Ryzumvi has received FDA approval for adult presbyopia, expanding its ophthalmic indications and creating a new commercial opportunity for Viatris. What to Watch Commercial partnership announcements, US launch plans, pricing, reimbursement, physician adoption and post-launch performance. Primary Source Viatris Primary Source URL https://newsroom.viatris.com/2026-10-16-Viatris-Receives-U-S-FDA-Approval-for-RYZUMVI-R-for-the-Treatment-of-Presbyopia Relevant Date 16 October 2026 Discover how nuaxia can support your next medical education initiative: Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector Contact us on: support@nuaxia.com


